Regeneron, Telix Pharmaceuticals to co-develop radiopharmaceutical cancer therapies

 

 in 50/50 collaboration with $40M upfront, up to $2.1B milestones plus royalties

• Collaboration uses a 50/50 cost and profit-sharing model between Regeneron and Telix Pharmaceuticals.
• Approval expands Dupixent’s EU label for chronic spontaneous urticaria to children aged 2 to 11.

https://finviz.com/quote.ashx?t=REGN&p=d